Skip to Content

How is Kymriah administered?

Answers (1)

Official Answer by 10 Oct 2017

Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in pediatric and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).

Kymriah is made from a patients own white blood cells in a process called leukapheresis. A tube (intravenous catheter) is placed in the patient's vein to collect the white blood cells from the blood. Leukapheresis takes 3 to 6 hours and may need to be repeated. The blood cells are frozen and sent to the manufacturing site to make Kymriah.

It takes roughly 3 to 4 weeks to make Kymriah. Before receiving Kymriah, a patient may receive chemotherapy for a few days to prepare their body to accept the treatment more readily. Once manufactured, Kymriah is given as a suspension through a tube (intravenous catheter) into the patient's vein. This usually takes less than one hour. However, once the patient receives Kymriah, they should plan to stay within 2 hours of their medical team and the location where they received the treatment for at least 4 weeks. free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 16 days ago 1 answerFAQ by

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 13 days ago 1 answerFAQ by

How do you use the ProAir Digihaler?

Updated 13 days ago 1 answerFAQ by

How many biosimilars have been approved in the United States?

Updated 12 days ago 1 answerFAQ by